Understanding Treatment Tolerability in Older Adults With Cancer

J Clin Oncol. 2021 Jul 1;39(19):2150-2163. doi: 10.1200/JCO.21.00195. Epub 2021 May 27.

Authors

Marie A Flannery¹, Eva Culakova², Beverly E Canin³, Luke Peppone², Erika Ramsdale⁴, Supriya G Mohile⁴

Affiliations

¹ University of Rochester Medical Center, School of Nursing, Rochester, NY.
² Department of Surgery, University of Rochester Medical Center, Rochester, NY.
³ SCOREboard Stakeholder Advisory Group, University of Rochester Medical Center, Rochester, NY.
⁴ Department of Medicine, University of Rochester, Rochester, NY.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Geriatric Assessment / methods*
Humans
Neoplasms / therapy*
Patient Reported Outcome Measures
Randomized Controlled Trials as Topic

Substances

Antineoplastic Agents

Grants and funding